Effect of β-Lactam Plus Macrolide Versus Fluoroquinolone on 30-Day Readmissions for Community-Acquired Pneumonia.
Sign Up to like & getrecommendations! Published in 2018 at "American Journal of Therapeutics"
DOI: 10.1097/mjt.0000000000000788
Abstract: BACKGROUND Antibiotic therapy with a macrolide and β-lactam or a fluoroquinolone for the empirical treatment of community-acquired pneumonia (CAP) in an inpatient non-intensive care setting is recommended per guidelines. Studies show that these treatments have… read more here.
Keywords: lactam plus; day readmissions; plus macrolide; day ... See more keywords
Is β-Lactam Plus Macrolide More Effective than β-Lactam Plus Fluoroquinolone among Patients with Severe Community-Acquired Pneumonia?: a Systemic Review and Meta-Analysis
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Korean Medical Science"
DOI: 10.3346/jkms.2017.32.1.77
Abstract: Adding either macrolide or fluoroquinolone (FQ) to β-lactam has been recommended for patients with severe community-acquired pneumonia (CAP). However, due to the limited evidence available, there is a question as to the superiority of the… read more here.
Keywords: lactam plus; patients severe; severe community; community acquired ... See more keywords
Beta-Lactam Plus Macrolide for Patients Hospitalized With Community-Acquired Pneumonia: Difference Between Autumn and Spring
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Korean Medical Science"
DOI: 10.3346/jkms.2022.37.e324
Abstract: Background The 2017 Korean guideline on community-acquired pneumonia (CAP) recommended beta-lactam plus macrolide combination therapy for patients hospitalized with severe pneumonia, and beta-lactam monotherapy for mild-to-moderate pneumonia. However, antibiotic treatment regimen for mild-to-moderate CAP has… read more here.
Keywords: plus macrolide; beta lactam; lactam plus; spring ... See more keywords